The outcome measures were evaluated at baseline, at the end of the last treatment session, and at 1-month follow-up visit.
A new sample can be compared with the baseline at the end of each day, providing a timely and effective operational damage detection method.
Neuropsychological tests and the 31-item Quality of Life in Epilepsy (QOLIE-31) inventory were administered at baseline, at the end of the short-term phase, and at the end of the long-term phase.
Serum HCV RNA levels increased by 0.5 log during therapy (mean HCV RNA day 0: 12.3 +/- 3.0 Meq/mL; 12 months: 38 Meq/mL; P <.05) and returned to baseline at the end of follow-up (11.0 +/- 2.4 Meq/mL).
The SF-36v2 forms were available to CH-1 study participants at baseline, at the end of the experimental period, and during the open-label period, as well as during follow-up at 12, 15, 18, 21, and 24 months.
Their stress and cognitive states were tested in the beginning to set a baseline, at the end of the classroom activities, and then again after a 10 minute break after the activities.
Moreover, the levels returned close to baseline at the end of the treatment (0.1 mg/dL).
The BPI was assessed at baseline, at the end of each cycle, and at the final visit.
However, the changes were transitory and oxygenation and haemodynamic parameters were similar to baseline at the end of the infusion.
Hematological parameters were determined during baseline, at the end of sepsis/VILI induction, and after three and six hours.
The number of patients with ≥50% increase of serum creatinine (SCr) from baseline at the end of the follow-up.
